# Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

> **NCT06515418** · PHASE2 · TERMINATED · sponsor: **BioAge Labs, Inc.** · enrollment: 204 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Oral Azelaprag (BGE-105)
- **DRUG:** Oral Placebo for Azelaprag (BGE-105)
- **DRUG:** Tirzepatide
- **DRUG:** Tirzepatide Placebo

## Key facts

- **NCT ID:** NCT06515418
- **Lead sponsor:** BioAge Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-27
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-12
- **Target enrollment:** 204 (ACTUAL)
- **Why stopped:** Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515418, "Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06515418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*